

## Inova Pulmonary Hypertension Program Publications 2013-2018

**Arun J, King CS, Shlobin OA, Brown AW, Wang C, Nathan SD.** Pulmonary Hemodynamic Responses Predict Outcomes in Patients with Fibrotic Lung Disease Undergoing Exercise Right Heart Catheterization Testing. *Eur Respir J* 2018 Sep 27;52(3)

**King CS, Brown AW, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Ahmad S, Nathan SD.** Prevalence and impact of WHO group 3 pulmonary Hypertension in advanced idiopathic nonspecific interstitial pneumonia. *Eur Respir J* 2018; 52:1800545(epub).

Baughman RP, **Shlobin OA**, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijnsbeek M, Ganesh S, Birring SS, Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engle PH, **Nathan SD.** Clinical Features of Sarcoidosis Associated Pulmonary Hypertension: Results of a Multi-National Registry. *Respiratory Medicine* 2018; 139:72-78.

Elinoff JM, Agarwal R, Barnett C, Benza RL, Cuttica MJ, Gharib AH, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig E, **Shlobin OA**, Steen VD, Zamanian RT, and Solomon MA. Challenges in Pulmonary Hypertension: Icebergs in the Water: A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. *AJRCCM* 2018 Jul 15; 198(2):166-174.

**Weir NA**, Conrey A, Lewis D, Mehari A. Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series. *Pulm Circ.* 2018 Oct-Dec; 8(4):2045894018791802 Jul 23 Epub.

Mehari A, Igbineweka N Dr, Allen D, Nichols J, Thein SL, **Weir NA.** Abnormal Ventilation-Perfusion Scan is Associated with Pulmonary Hypertension in Sickle Cell Adults. *J Nucl Med* 2018 Jun 7 Epub.

Elinoff JM, Chen LY, Dougherty EJ, Awad KS, Wang S, Biancotto A, Siddiqui AH, **Weir NA**, Cai R, Sun J, Preston IR, Solomon MA, Danner RL. Spironolactone-induced degradation of the TFIID core complex XPB subunit suppresses NF- $\kappa$ B and AP-1 signalling. *Cardiovasc Res.* 2018 Jan 1;114(1):65-76.

Woolstenhulme JG, Guccione AA, Herrick JE, Collins JP, **Nathan SD**, Chan LE, Keyser RE. Left Ventricular Function Before and After Aerobic Exercise Training in Women Who Have Pulmonary Arterial Hypertension. Accepted to *Journal of Cardiopulmonary Rehabilitation and Prevention* 2018.

Behr J, **Nathan SD**, Harari S, Wyuts W, Kirchgaessler K, Bengus M, Gilberg F, Wells A. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and pulmonary hypertension: A Phase IIb randomised double-blind placebo-controlled study. *Respir Med* 2018 May; 138:13-20.

Jose A, **King C, Shlobin OA, Kiernan J, Cossa N, Nathan SD.** Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension. *Chest* 2017; 152(5):980-989.

**Shlobin OA**, Baughman R. Sarcoidosis Associated Pulmonary Hypertension. *Seminars in Respiratory Critical Care Medicine* 2017; 38:450-462.

**Shlobin OA**, Brown AW, **Nathan SD**. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. Chest 2017 Jan; 151(1):204-214.

John H. Newman, Stuart Rich, Steven H. Abman, John H. Alexander, John Barnard, Gerald J. Beck, Raymond L. Benza, Todd M. Bull, Stephen Y. Chan, Hyung J. Chun, Declan Doogan, Jocelyn Dupuis, Scott S. Emerson, Serpil C. Erzurum, Robert P. Frantz, Mark Geraci, Hunter Gillies, Mark Gladwin, Michael P. Gray, Anna Hemnes, Roy S. Herbst, Adrian F. Hernandez, Nicholas S. Hill, Evelyn M. Horn, Kendall Hunter, Zhi-Cheng Jing, Roger Johns, Sanjay Kaul, Steven Kawut, Tim Lahm, Jane A. Leopold, Greg D. Lewis, Stephen C. Mathai, Vallerie V. McLaughlin, Evangelos D. Michelakis, **Steven D. Nathan**, William Nichols, Grier Page, Marlene Rabinovitch, Jonathan Rich, Franz Rischard, Sharon Rounds, Sanjiv J. Shah, Victor F. Tapson, Naomi Lowy, Norman Stockbridge, Gail Weinmann, Lei Xiao. Enhancing Treatments for Pulmonary Vascular Diseases (PVD) Through Precision Medicine. A Joint NHLBI-CMREF Workshop Report. Am J Respir Crit Care Med 2017; 195:1661-1670.

**Weir NA**, Saiyed R, Alam S, Conrey A, Desai HD, George MP, Keeley JH, Klings ES, Mehari A, Taylor JG 6th, Minniti CP, Kato GJ. Prostacyclin-analog therapy in sickle cell pulmonary hypertension. Haematologica 2017 May; 102(5):e163-e165.

Pittman C, Hsieh MM, Coles W, Tisdale JF, **Weir NA**, Fitzhugh CD. Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant 2017Apr; 52(4):641-642.

Kearon C, Akl E, Ornelas J, Blaivas A, Jiminez D, Bounameaux H, Huisman M, **King CS**, Morris TA, Sood N, Stevens S, Vintch JR, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE Disease: Chest Guideline and Expert Panel Report. Chest 2016; 149(2): 315-352.

Shin S, **King CS**, Puri N, **Shlobin OA**, **Brown AW**, Ahmad S, **Weir N**, **Nathan SD**. Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47:1445–1451.

Fischer A, Gillies H, Blair C, Tislow JD, **Nathan SD**. Ambrisentan Response in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension- Subgroup Analysis of the ARIES-E Clinical Trial. Respiratory Medicine 2016; 117:254-263.

Raghu G, **Nathan SD**, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, WellsAU, Shao L, Zhang H, Henig N, Szwarcberg J, Gillies H, Montgomery AB, O’Riordan TG. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild to moderate restriction. Eur Respir J 2015 46(5):1370-7

Shin S, **King CS**, **Brown AW**, **Albano MC**, **Atkins M**, **Sheridan M**, Ahmad S, Newton K, **Weir N**, **Shlobin OA**, **Nathan SD**. Pulmonary Artery Size As A Predictor Of Pulmonary Hypertension And Outcomes In Patients With Chronic Obstructive Pulmonary Disease. Respir Med 2014 Nov; 108(11):1626-32.

**King CS**, May CW, Williams J, **Shlobin OA**. Management of right heart failure in the critically ill. Crit Care Clin 2014; 30(3): 475-98.

**Nathan SD, King CS.** Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? *Drug Des Devel Ther* 2014; 8:875-85.

Corson N, Armato SG 3rd, Labby ZE, Straus C, Starkey A, **Gomberg-Maitland M.** CT-based pulmonary artery measurements for the assessment of pulmonary hypertension. *Acad Radiol* 2014 Apr; 21(4):523-30.

**Weir N, Brown AW, Shlobin OA, Smith M, Reffett T, Battle E,** Ahmad S, **Nathan SD.** Influence of alternative instruction on the six minute walk test distance. *Chest* 2013; 144(6):1900-1905.

Chan L, Chin LMK, Kennedy M, Woolstenhulme JG, **Nathan SD,** Weinstein AA, Connors G, **Weir NA,** Drinkard B, **Lamberti J,** Keyser RE. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. *Chest* 2013 Feb 1; 143(2):333-343.